British-Swedish pharmaceutical giant AstraZeneca said on Thursday it plans to invest US$15 billion in China through 2030, signalling renewed momentum in Sino-UK commercial ties. The investment – the biggest deal announced so far during UK Prime Minister Keir Starmer’s trip to Beijing aimed at strengthening trade ties – will support expanded medicines manufacturing as well as research and development (R&D), the company said in a statement. “Unlocking opportunities for British businesses across...